MEDIGENE AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.505 EUR | -5.64% |
|
-21.61% | -1.31% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Medigene R&D event. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Calendar
2024-05-01
- Neoantigen International Summit
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.505
EUR
Average target price
2.675
EUR
Spread / Average Target
+77.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.31% | 39.46M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Transcript : Medigene AG - Special Call
